Checkpoint Therapeutics (NASDAQ:CKPT) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock opened at $2.06 on Monday. The firm’s fifty day moving average price is $1.77 and its 200-day moving average price is $1.94. The stock has a market cap of $73.52 million, a P/E ratio of -0.74 and a beta of 1.13. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. On average, analysts predict that Checkpoint Therapeutics will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several hedge funds have recently bought and sold shares of CKPT. Armistice Capital LLC raised its holdings in Checkpoint Therapeutics by 46.1% in the third quarter. Armistice Capital LLC now owns 2,064,000 shares of the company’s stock worth $3,509,000 after buying an additional 651,000 shares during the last quarter. Choreo LLC purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $44,000. B. Riley Wealth Advisors Inc. raised its holdings in shares of Checkpoint Therapeutics by 232.3% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock valued at $374,000 after purchasing an additional 114,200 shares during the last quarter. Magnus Financial Group LLC purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $55,000. Finally, Sabby Management LLC purchased a new position in shares of Checkpoint Therapeutics during the third quarter valued at approximately $349,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.